Momekort (Mometasone Furoate Monohydrate)

Mometasone furoate monohydrate, the active ingredient in Momekort, is a corticosteroid presented as a nasal spray for nasal use. It treats allergic rhinitis, nasal polyps, and non‑allergic rhinitis in adults and children.

GNH USA supplies Momekort as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Momekort is a corticosteroid nasal spray indicated for several inflammatory conditions of the nasal passages. - Allergic rhinitis (seasonal and perennial): Reduces nasal congestion, itching, sneezing and rhinorrhea. - Nasal polyps: Decreases polyp size and improves airflow, helping to relieve obstruction. - Non‑allergic rhinitis: Alleviates chronic nasal inflammation and associated symptoms such as congestion and post‑nasal drip.

Momekort may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation - Epistaxis (nosebleeds) - Headache - Throat irritation or dryness - Cough - Altered taste perception

Serious or Rare Side Effects: - Adrenal suppression with prolonged high‑dose use - Cataracts or glaucoma - Fungal infection of the nasal passages - Severe nasal septum perforation - Systemic immunosuppression leading to increased infection risk - Hypersensitivity reactions including angioedema

Before using Momekort, consider the following precautions. - Pregnancy: Consult a healthcare professional; safety data are limited. - Elderly patients: Monitor for systemic corticosteroid effects. - Nasal surgery or trauma: Delay use until healing is complete. - Active nasal infection: Avoid until infection resolves. - Concomitant systemic corticosteroids: Assess cumulative steroid exposure. - Store at room temperature: Keep in the original container, protect from moisture and heat.

Momekort can interact with other medicines that affect corticosteroid activity or metabolism.

Major Interactions (Avoid): - Systemic corticosteroids: Increased risk of systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): May raise systemic exposure.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): Monitor for enhanced effects. - Antifungal azoles: Potential increase in mometasone levels. - Ritonavir: May elevate systemic concentrations. - Immunosuppressants (e.g., cyclosporine): Watch for additive immunosuppression.